secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2022-06-29T23:59:59+00:00
Accession:  0001104659-22-075345
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VTP-300 shows durable HBsAg reductions in chronic hepatitis B; no serious adverse events
--------------------------------------------------------------------------------

- Updated interim data (n=39) shows VTP-300 as monotherapy or +nivolumab had no treatment-related SAEs; 2 mild transaminitis cases.
- In monotherapy, 3 patients with baseline HBsAg <50 IU/mL had 0.7-1.4 log10 declines durable up to 8 months.
- Combination group (8 patients) had mean HBsAg reduction >1 log10 at 6 months, persisting to 1.15 log10 at 8 months.
- Robust T cell response with marked CD8+ predominance observed; enrollment complete at 55 patients.
- Updated interim analysis for all patients at 6-month follow-up expected end of 2022; new trial dosing expected Q3 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000110465922075345/0001104659-22-075345-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000110465922075345/tm2219878d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-075345

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer